


Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1. (original) A dicarboxylic acid salt of sibutramine, represented by the following Chemical Formula 1:

Chemical Formula 1




wherein, n is an integral number of 0 or 1.

2. (original) The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine oxalate having an X-ray diffraction pattern in which peaks appear at 2θ values of 5.46, 10.92, 12.16, 12.74, 14.92, 15.44, 15.78, 17.4, 19.24, 21.3, 22.0, 22.92, 24.54, 25.3, 25.8, 27.52, 28.74, 28.92, 30.12, 33.26, 35.04, and 39.76.
3. (original) The dicarboxylic acid salt of sibutramine as set forth in claim 1, which is sibutramine malonate having an X-ray diffraction pattern in which peaks appear at 2θ values of 7.7, 10.74, 11.08, 11.56, 15.42, 15.78, 17.24, 17.84, 18.1, 19.02, 19.68, 21.54, 21.9, 22.24, 22.88, 23.26, 23.64, 24.44, 24.72, 26.0, 27.6, 28.4, 28.62, and 29.3.

4. (currently amended) A method of preparing ~~the dicarboxylic acid salt of~~
~~sibutramine represented by a dicarboxylic acid salt of sibutramine represented by the~~
following Chemical Formula 1: Chemical Formula 1 according to claim 1,

Chemical Formula 1




wherein, n is an integral number of 0 or 1

comprising reacting sibutramine with a dicarboxylic acid selected from among oxalic acid and malonic acid in an inert solvent.

5. (currently amended) A pharmaceutical composition ~~for treating or preventing obesity and related disorders, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising the~~ comprising a dicarboxylic acid salt of sibutramine represented by the following Chemical Formula 1: Chemical Formula 1 according to claim 1

Chemical Formula 1




wherein, n is an integral number of 0 or 1

as an effective ingredient and a pharmaceutically acceptable diluent or carrier.

6. (original) The pharmaceutical composition as set forth in claim 5, which is formulated into tablets or capsules.

7. (currently amended) A method of treating ~~or preventing~~ obesity and ~~related disorders~~, depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy, comprising administering the pharmaceutical composition ~~of claim 5~~, comprising the dicarboxylic acid salt of sibutramine represented by the following Chemical Formula 1:

Chemical Formula 1



wherein, n is an integral number of 0 or 1

as an effective ingredient.

8. (new) The pharmaceutical composition as set forth in claim 5, wherein the composition is for treating obesity, depression, Parkinson's disease, insulin-independent diabetes mellitus, or epilepsy.